MEDP
Medpace Holdings, Inc. · Healthcare · Medical - Diagnostics & Research
Alle eigendomscijfers: uitsluitend gevolgde 13F-managers, posities in gewone aandelen, rapportageperiode Q2 2024
| Kwartaal | Houders | Δ | Aandelen | Gerapporteerde waarde | Nieuw | Uitstappen |
|---|---|---|---|---|---|---|
| Q2 2026 | 131 | -10 | 16.81M | $8.90B | +3 | −12 |
| Q1 2026 | 143 | -2 | 15.75M | $7.54B | +5 | −8 |
| Q4 2025 | 145 | 0 | 17.01M | $9.56B | +1 | — |
| Q3 2025 | 22 | 0 | 10.56M | $5.42B | +1 | −2 |
| Q2 2025 | 20 | +1 | 9.67M | $3.03B | +1 | — |
| Q1 2025 | 16 | -1 | 3.77M | $1.14B | — | −1 |
| Q4 2024 | 17 | +1 | 4.06M | $1.35B | +1 | — |
| Q3 2024 | 15 | -1 | 3.56M | $1.19B | — | −1 |
| Q2 2024 | 16 | — | 3.05M | $1.26B | — | — |
| # | Manager | Aandelen | Δ aandelen | Waarde | Hun gewicht | Gehouden | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Geode Capital Management ✦ (passief) | 583.68K | — | $240.63M | 0.0% | n/c | 1 | SEC ↗ |
| 2 | Geode Capital Management ✦ (passief) | 583.68K | — | $240.63M | 0.0% | n/c | 1 | SEC ↗ |
| 3 | Renaissance Technologies ✦ | 443.59K | — | $182.69M | 0.3% | n/c | 1 | SEC ↗ |
| 4 | AQR Capital Management ✦ | 310.65K | — | $127.94M | 0.2% | n/c | 1 | SEC ↗ |
| 5 | AQR Capital Management ✦ | 310.65K | — | $127.94M | 0.2% | n/c | 1 | SEC ↗ |
| 6 | AQR Capital Management ✦ | 310.65K | — | $127.94M | 0.2% | n/c | 1 | SEC ↗ |
| 7 | Wellington Management ✦ | 305.37K | — | $125.77M | 0.0% | n/c | 1 | SEC ↗ |
| 8 | Wellington Management ✦ | 305.37K | — | $125.77M | 0.0% | n/c | 1 | SEC ↗ |
| 9 | Wellington Management ✦ | 305.37K | — | $125.77M | 0.0% | n/c | 1 | SEC ↗ |
| 10 | Wellington Management ✦ | 305.37K | — | $125.77M | 0.0% | n/c | 1 | SEC ↗ |
| 11 | D. E. Shaw & Co. ✦ | 299.87K | — | $123.50M | 0.2% | n/c | 1 | SEC ↗ |
| 12 | D. E. Shaw & Co. ✦ | 299.87K | — | $123.50M | 0.2% | n/c | 1 | SEC ↗ |
| 13 | Norges Bank ✦ (passief) | 279.58K | — | $115.15M | 0.0% | n/c | 1 | SEC ↗ |
| 14 | Arrowstreet Capital ✦ | 237.35K | — | $97.75M | 0.1% | n/c | 1 | SEC ↗ |
| 15 | T. Rowe Price ✦ | 154.29K | — | $63.54M | 0.0% | n/c | 1 | SEC ↗ |
| 16 | T. Rowe Price ✦ | 154.29K | — | $63.54M | 0.0% | n/c | 1 | SEC ↗ |
| 17 | Two Sigma Investments ✦ | 123.80K | — | $50.99M | 0.1% | n/c | 1 | SEC ↗ |
| 18 | Fisher Asset Management ✦ | 116.39K | — | $47.93M | 0.0% | n/c | 1 | SEC ↗ |
| 19 | Millennium Management ✦ | 109.80K | — | $45.22M | 0.0% | n/c | 1 | SEC ↗ |
| 20 | Point72 Asset Management ✦ | 62.43K | — | $25.71M | 0.1% | n/c | 1 | SEC ↗ |
| 21 | Citadel Advisors ✦ | 9.65K | — | $3.98M | 0.0% | n/c | 1 | SEC ↗ |
| 22 | Gotham Asset Management ✦ | 5.88K | — | $2.42M | 0.0% | n/c | 1 | SEC ↗ |
| 23 | Baillie Gifford ✦ | 5.40K | — | $2.22M | 0.0% | n/c | 1 | SEC ↗ |
| 24 | Baillie Gifford ✦ | 5.40K | — | $2.22M | 0.0% | n/c | 1 | SEC ↗ |
| 25 | Capital World Investors ✦ | 615 | — | $253,288 | 0.0% | n/c | 1 | SEC ↗ |
"Hun gewicht" = het aandeel van de positie in de gerapporteerde 13F-aandelenwaarde van die beheerder — de overtuigingsmaatstaf. ✦ = gecureerde beheerder.
Nieuwe kopers
| Geen nieuwe bijgehouden kopers dit kwartaal. |
Verlaten
| Geen bijgehouden uitstappen dit kwartaal. |
Volledige marktcontext: over ALLE 13F-indieners (SEC gestructureerde data, Q1 2026): 724 houders, 23.89M aandelen, $10.71B gerapporteerd. Dit betreft een andere, oudere periode dan de bovenstaande cijfers van het gevolgde universum; beide worden nooit gecombineerd.
Wat de gevolgde houders van dit effect verder het vaakst bezitten — aantallen gedeeld eigendom, geen fundamentele relaties.
Open-market aankopen (P)
Geen open-market insider-aankopen in ons dekkingsvenster.
Open-market verkopen (S)
Officer, Director, 10% owner · 1.98K aand · $1.23M
Officer, Director, 10% owner · 13.99K aand · $8.74M
Officer · 3.40K aand · $2.13M
Officer, Director, 10% owner · 27.17K aand · $16.81M
Director · 7.28K aand · $4.41M
Officer, Director, 10% owner · 15.61K aand · $9.47M
Director · 5.00K aand · $3.04M
Officer, Director, 10% owner · 458 aand · $274,979
Officer, Director, 10% owner · 11.37K aand · $6.84M
Director · 1.14K aand · $690,122
Toekenningen, uitoefeningen en belastinginhoudingen worden hier nooit meegeteld als aankopen of verkopen. Methodologie